Skip NavigationSkip to Content
Return Return to Search Results

Functional Redundancy of Exon 12 of BRCA2 Revealed by a Comprehensive Analysis of the c.6853A > G (p.I2285V) Variant

  1. Author:
    Li, L. L.
    Biswas, K.
    Habib, L. A.
    Kuznetsov, S. G.
    Hamel, N.
    Kirchhoff, T.
    Wong, N.
    Armel, S.
    Chong, G.
    Narod, S. A.
    Claes, K.
    Offit, K.
    Robson, M. E.
    Stauffer, S.
    Sharan, S. K.
    Foulkes, W. D.

  2. Author Address

    Wong, Nora, Foulkes, William D.] SMBD Jewish Gen Hosp, Canc Prevent Ctr, Montreal, PQ H3T 1E2, Canada. [Wong, Nora, Foulkes, William D.] SMBD Jewish Gen Hosp, Dept Med Genet, Montreal, PQ H3T 1E2, Canada. [Li, Lili, Habib, Laura Anne, Foulkes, William D.] McGill Univ, Dept Oncol, Program Canc Genet, Montreal, PQ, Canada. [Li, Lili, Habib, Laura Anne, Foulkes, William D.] McGill Univ, Dept Human Genet, Program Canc Genet, Montreal, PQ, Canada. [Biswas, Kajal, Kuznetsov, Sergey G.; Stauffer, Stacey, Sharan, Shyam K.] NCI, Mouse Canc Genet Program, Ctr Canc Res, Frederick, MD 21701 USA. [Hamel, Nancy, Foulkes, William D.] McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ, Canada. [Kirchhoff, Tomas, Offit, Kenneth, Robson, Mark E.] Mem Sloan Kettering Canc Ctr, Clin Genet Serv, New York, NY 10021 USA. [Armel, Susan] Univ Toronto, Princess Margaret Hosp, Familial Breast & Ovarian Canc Clin, Toronto, ON M5S 1A1, Canada. [Chong, George] SMBD Jewish Gen Hosp, Dept Pathol, Montreal, PQ H3T 1E2, Canada. [Narod, Steven A.] Univ Toronto, Womens Coll Hosp, Res Inst, Toronto, ON M5S 1A1, Canada. [Claes, Kathleen] Ghent Univ Hosp, Ctr Med Genet, Ghent, Belgium.
    1. Year: 2009
  2. Journal: Human Mutation
    1. 30
    2. 11
    3. Pages: 1543-1550
  4. Type of Article: Article
  1. Abstract:

    Variants of unknown significance (VUS) in BRCA1 and BRCA2 are common, and present significant challenges for genetic counseling. We observed that BRCA2: c.6853A>G (p.I2285V) (Breast Cancer Information Core [BIC] name: 7081A > G, http://research.nhgri.nih.gov/bic/) co-occurs in trans with the founder mutation c.5946delT (p.S1982RfsX22) (BIC name: 6174deIT), supporting the published classification of p.I2285V as a neutral variant. However, we also noted that when compared with wild,type BRCA2, p.I2285V resulted in increased exclusion of exon 12. Functional assay using allelic complementation in Brca2-null mouse embryonic stern cells revealed that p.I2285V, an allele with exon 12 deleted and wild-type BRCA2 were all phenotypically indistinguishable, as measured by sensitivity to DNA-damaging agents, effect on irradiation-induced Rad51. foci formation, homologous recombination, and overall genontic integrity. An allele frequency study showed the p.I2285V variant was identified in 15 out of 722 (2.1%) Ashkenazi Jewish cases and 10 out of 475 (2.1%) ethnically,matched controls (odds ratio, 0.99, 95% confidence interval: 0.44-2.21, P = 0.97). Thus the p.I2285V variant is not associated with an increased risk for breast cancer. Taken together, our clinical and functional studies strongly suggest that exon 12 is functionally redundant and therefore missense variants in this exon are likely to be neutral. Such comprehensive functional studies will be important adjuncts to genetic studies of variants. Hum Mutat 30:1543-1550, 2009. Published 2009 Wiley-Liss, Inc.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1002/humu.21101
  3. PMID: 19795481

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel